--- title: "Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References" description: "Reference list for the formulary evidence report on Hibsago (bepirovirsen, GSK3228836) in Chronic hepatitis B virus infection in adults without cirrhosis. 190 cited documents." canonical: "https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references" published: "2026-10-21T22:39:04-04:00" modified: "2026-10-22T19:07:03-04:00" --- # Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References ## 5 References 1. [Agarwal et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583491/) 2. [Anderson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12265875/) 3. [Bixler et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11230463/) 4. [Bixler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10069827/) 5. [Bouquet et al. (2026)](https://doi.org/10.1016/j.jhep.2025.12.025) 6. [Buti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11599788/) 7. [Buti et al. (2025)](https://doi.org/10.1016/j.jhep.2024.08.010) 8. [CDA-AMC bepirovirsen reimbursement review (2026)](https://www.cda-amc.ca/bepirovirsen) 9. [CDC Clinical Care of Hepatitis B (2025)](https://www.cdc.gov/hepatitis-b/hcp/clinical-care/index.html) 10. [CDC Clinical Overview of Hepatitis B (2025)](https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html) 11. [CDC Clinical Signs and Symptoms of Hepatitis B (2025)](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html) 12. [CDC Clinical Testing and Diagnosis for Hepatitis B (2026)](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html) 13. [CDC guidelines and quality measures (2026)](https://www.cdc.gov/high-quality-care/hcp/guidelines-quality-measures.html) 14. [CDC Viral Hepatitis Surveillance Report (2025)](https://www.cdc.gov/hepatitis-surveillance-2023/hepatitis-b/index.html) 15. [CDC Viral Hepatitis Surveillance Report national profile (2025)](https://www.cdc.gov/hepatitis-surveillance-2023/about/national-profile.html) 16. [Chen et al. (2006)](https://doi.org/10.1001/jama.295.1.65) 17. [Cheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13594892/) 18. [Clinical Pharmacology in Drug Development (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13169179/) 19. [ClinicalTrials.gov NCT02981602](https://clinicaltrials.gov/study/NCT02981602) 20. [ClinicalTrials.gov NCT02981602](https://clinicaltrials.gov/study/NCT02981602?tab=results) 21. [ClinicalTrials.gov NCT04449029](https://clinicaltrials.gov/study/NCT04449029) 22. [ClinicalTrials.gov NCT04449029](https://clinicaltrials.gov/study/NCT04449029?tab=results) 23. [ClinicalTrials.gov NCT04544956](https://clinicaltrials.gov/study/NCT04544956) 24. [ClinicalTrials.gov NCT04544956](https://clinicaltrials.gov/study/NCT04544956?tab=results) 25. [ClinicalTrials.gov NCT04676724](https://clinicaltrials.gov/study/NCT04676724) 26. [ClinicalTrials.gov NCT04676724](https://clinicaltrials.gov/study/NCT04676724?tab=results) 27. [ClinicalTrials.gov NCT04954859](https://clinicaltrials.gov/study/NCT04954859) 28. [ClinicalTrials.gov NCT04971928](https://clinicaltrials.gov/study/NCT04971928) 29. [ClinicalTrials.gov NCT05276297](https://clinicaltrials.gov/study/NCT05276297) 30. [ClinicalTrials.gov NCT05276297](https://clinicaltrials.gov/study/NCT05276297?tab=results) 31. [ClinicalTrials.gov NCT05630807](https://clinicaltrials.gov/study/NCT05630807) 32. [ClinicalTrials.gov NCT05630820](https://clinicaltrials.gov/study/NCT05630820) 33. [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390) 34. [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390?tab=results) 35. [ClinicalTrials.gov NCT06422767](https://clinicaltrials.gov/study/NCT06422767?tab=results) 36. [ClinicalTrials.gov NCT06422767](https://clinicaltrials.gov/study/NCT06422767) 37. [ClinicalTrials.gov NCT06497504](https://clinicaltrials.gov/study/NCT06497504) 38. [ClinicalTrials.gov NCT06537414](https://clinicaltrials.gov/study/NCT06537414) 39. [ClinicalTrials.gov NCT07168356](https://clinicaltrials.gov/study/NCT07168356) 40. [CMS (2025)](https://www.medicaid.gov/federal-policy-guidance/downloads/sho25005.pdf) 41. [CMS 2027 Adult Core Set](https://www.medicaid.gov/medicaid/quality-of-care/downloads/2027-adult-core-set.pdf) 42. [Congly et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38710472/) 43. [Conners et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9997714/) 44. [Cremer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427703/) 45. [Delahaye et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13676563/) 46. [Dongelmans et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13638273/) 47. [Drysdale et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13179525/) 48. [EASL (2025)](https://doi.org/10.1016/j.jhep.2025.03.018) 49. [EMA paediatric investigation plan decision P/0254/2022 (2022)](https://www.ema.europa.eu/en/documents/pip-decision/p-254-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bepirovirsen-emea-003082-pip01-21_en.pdf) 50. [Ermler et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13482607/) 51. [EU Clinical Trials Information System 2023-504238-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-504238-23-00) 52. [EU Clinical Trials Information System 2023-504239-41-00](https://euclinicaltrials.eu/ctis-public/view/2023-504239-41-00) 53. [EU Clinical Trials Register 2021-005139-22](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005139-22/GR) 54. [EU Clinical Trials Register 2022-002268-53](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002268-53/BG) 55. [FDA guidance on chronic hepatitis B drug development (2022)](https://www.fda.gov/media/117977/download) 56. [FDA Hibsago approval announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment) 57. [FDA Novel Drug Approvals for 2026 (2026)](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) 58. [Fierce Pharma (2026)](https://www.fiercepharma.com/pharma/gsk-brings-promise-functional-cure-hepatitis-b-finish-line-fda-nod-hibsago) 59. [Freeland et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8581088/) 60. [Freeland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11167835/) 61. [Fu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11919624/) 62. [Gadano et al. (2023)](https://www.postersessiononline.eu/173580348_eu/congresos/ILC2023/aula/-LBP_15_ILC2023.pdf) 63. [Gane et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12409438/) 64. [Gane et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42214405/) 65. [Gane et al. (2026b)](https://doi.org/10.1097/HEP.0000000000001835) 66. [GBD 2019 Hepatitis B Collaborators (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9349325/) 67. [Ghany et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12373085/) 68. [Ghany et al. (2026)](https://doi.org/10.1097/HEP.0000000000001549) 69. [Gilead Sciences (2024)](https://www.gilead.com/-/media/files/pdfs/other/vemlidy-long-form.pdf) 70. [Gish et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020024/) 71. [GSK 205873 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/67/NCT06422767/Prot_000.pdf) 72. [GSK 209348 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/24/NCT04676724/Prot_000.pdf) 73. [GSK 209668 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/29/NCT04449029/Prot_000.pdf) 74. [GSK 209668 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/29/NCT04449029/SAP_001.pdf) 75. [GSK 212602 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/56/NCT04544956/Prot_000.pdf) 76. [GSK 219239 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/90/NCT06058390/Prot_000.pdf) 77. [GSK FY2023 results slides (2024)](https://www.gsk.com/media/afnjlfik/fy-2023-results-slides.pdf) 78. [GSK FY2025 pipeline assets and clinical trials appendix (2026)](https://www.gsk.com/media/rs0mbgqw/fy-2025-pipeline-assets-and-clinical-trials-report.pdf) 79. [GSK press release, AASLD 2025 (2025)](https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-from-its-advancing-liver-pipeline-at-aasld-2025/) 80. [GSK press release, B-Clear results (2022)](https://www.gsk.com/en-gb/media/press-releases/positive-data-for-bepirovirsen-from-b-clear-phase-iib-trial/) 81. [GSK press release, B-Well results (2026)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/) 82. [GSK press release, B-Well topline (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/) 83. [GSK press release, China acceptance (2026)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-china-as-a-potential-first-in-class-functional-cure-for-chronic-hepatitis-b/) 84. [GSK press release, EMA acceptance (2026)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-review-by-the-european-medicines-agency-as-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/) 85. [GSK press release, Fast Track designation (2024)](https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/) 86. [GSK press release, FDA priority review (2026)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-the-us-fda/) 87. [GSK press release, Hibsago Japan approval (2026)](https://www.gsk.com/en-gb/media/press-releases/hibsago-bepirovirsen-approved-in-japan-as-first-and-only-functional-cure-for-chronic-hepatitis-b/) 88. [GSK press release, Hibsago US approval (2026)](https://www.gsk.com/en-gb/media/press-releases/hibsago-bepirovirsen-approved-in-the-us-for-the-treatment-of-chronic-hepatitis-b-chb/) 89. [GSK press release, Japan acceptance (2026)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-japan/) 90. [GSK press release, SBP Group collaboration (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-collaboration-with-sbp-group-a-market-leader-in-hepatology-in-china-to-accelerate-bepirovirsen-at-launch/) 91. [GSK press release, SENKU designation (2024)](https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-granted-senku-designation-in-japan-for-chronic-hepatitis-b/) 92. [GSK Q1 2026 results (2026)](https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf) 93. [GSK Q2 2026 results (2026)](https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf) 94. [Han et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9804925/) 95. [Han et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975176/) 96. [HHS Viral Hepatitis National Strategic Plan (2020)](https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf) 97. [Hibsago prescribing information (2026)](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Hibsago/pdf/HIBSAGO-PI-MG-IFU.PDF) 98. [Hirode et al. (2022)](https://doi.org/10.1053/j.gastro.2021.11.002) 99. [Hoofnagle (2022)](https://pubmed.ncbi.nlm.nih.gov/36346068/) 100. [Hou et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39774313/) 101. [Hou et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42206582/) 102. [Hou et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42777251/) 103. [Hui et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11750937/) 104. [Hutton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9188991/) 105. [Iannacone and Guidotti (2022)](https://pubmed.ncbi.nlm.nih.gov/34002067/) 106. [Iloeje et al. (2006)](https://doi.org/10.1053/j.gastro.2005.11.016) 107. [Ionis ISIS 505358-CS3 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT02981602/Prot_002.pdf) 108. [Ionis press release, GSK license (2019)](https://ir.ionis.com/node/25196) 109. [Ionis press release, Hibsago US approval (2026)](https://ir.ionis.com/news-releases/news-release-details/ionis-partner-gsk-announces-hibsago-bepirovirsen-approved-us) 110. [Ionis press release, phase 3 start (2023)](https://ir.ionis.com/node/29351) 111. [Jeng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13496306/) 112. [Joshi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12923464/) 113. [Kaushik et al. (2024)](https://doi.org/10.1016/j.jval.2024.06.002) 114. [KEGG DRUG D12615](https://www.kegg.jp/entry/D12615) 115. [Kim et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24162593/) 116. [Kim et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30106839/) 117. [Kudaravalli et al. (2024)](https://doi.org/10.1016/j.jhep.2024.02.033) 118. [Lai et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39577468/) 119. [Lau et al. (2005)](https://doi.org/10.1056/NEJMoa043470) 120. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11257816/) 121. [Lens (2023)](https://pubmed.ncbi.nlm.nih.gov/36801391/) 122. [Lens (2026)](https://pubmed.ncbi.nlm.nih.gov/42480667/) 123. [Levy et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18179664/) 124. [Lim et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32483003/) 125. [Lim et al. (2025a)](https://ionis.com/sites/default/files/2026-06/Lim%20et%20al%20-%20UP%20to%202%20years%20functional%20cure%20in%20response%20to%20bepirovirsen%20therapy%20in%20B-Clear%20Not-on-NA%20responders%20-%20B%20Sure%20third%20report.pdf) 126. [Lim et al. (2025b)](https://ionis.com/sites/default/files/2026-06/Lim%20et%20al%20-%20Up%20to%2018%20months%20functional%20cure%20in%20response%20to%20bepirovirsen%20therapy%20in%20B-Clear%20on%20NA%20responders%20-%20B-Sure%20third%20report.pdf) 127. [Lok (2026)](https://pubmed.ncbi.nlm.nih.gov/42206569/) 128. [Lok et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6294322/) 129. [Low et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11973283/) 130. [Ly et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9240905/) 131. [Mak et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37902953/) 132. [Marcellin et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15371578/) 133. [Mathematica (2025)](https://www.mathematica.org/-/media/internet/features/2025/child-and-adult-core-set/2027coresetreview-finalreport_updated.pdf) 134. [MHLW Chuikyo DPC high-cost new drugs (2026)](https://www.mhlw.go.jp/content/10808000/001756861.pdf) 135. [MHLW Chuikyo new drug price listing (2026)](https://www.mhlw.go.jp/content/10808000/001756860.pdf) 136. [Nguyen et al. (2019)](https://doi.org/10.1016/j.jhep.2018.09.021) 137. [Nguyen et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7048015/) 138. [Nguyen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9701467/) 139. [NICE ID6608](https://www.nice.org.uk/guidance/indevelopment/gid-ta11803) 140. [NIHR Innovation Observatory (2025)](https://io.nihr.ac.uk/wp-content/uploads/2025/04/30147-Bepirovirsen-for-Chronic-Hepatitis-B-V1.0-APR2025-NON-CONF.pdf) 141. [Noormohamed et al. (2024)](https://doi.org/10.1002/cpdd.1454) 142. [ODPHP Healthy People 2030 IID-13](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/increase-proportion-people-who-know-they-have-chronic-hepatitis-b-iid-13) 143. [ODPHP Healthy People 2030 IID-15](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/reduce-rate-deaths-hepatitis-b-cause-iid-15) 144. [Pan et al. (2026)](https://doi.org/10.1097/HEP.0000000000001584) 145. [Papatheodoridis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42409322/) 146. [Pharmaphorum (2026)](https://pharmaphorum.com/news/gsk-hails-unprecedented-cure-rates-hep-b-drug) 147. [Pirzada et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42832798/) 148. [Polaris Observatory Collaborators (2023)](https://pubmed.ncbi.nlm.nih.gov/37517414/) 149. [Razavi-Shearer et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10239007/) 150. [Razavi-Shearer et al. (2023b)](https://doi.org/10.1111/jvh.13843) 151. [Razavi-Shearer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715829/) 152. [Revill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6732795/) 153. [Roberts et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34097776/) 154. [Salem et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41826491/) 155. [Sbarigia et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7089729/) 156. [Smith-Palmer et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7082540/) 157. [Song et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986681/) 158. [Spencer-Dene et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10578491/) 159. [Terrault et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5975958/) 160. [Toy et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/33956937/) 161. [Toy et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/34328697/) 162. [Toy et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12598672/) 163. [US Preventive Services Task Force (2020)](https://pubmed.ncbi.nlm.nih.gov/33320230/) 164. [Vaillant (2023)](https://pubmed.ncbi.nlm.nih.gov/36947477/) 165. [Vir Biotechnology press release (2025)](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-Preliminary-24-Week-Post-End-of-Treatment-Data-for-Tobevibart-and-Elebsiran-Combinations-in-Chronic-Hepatitis-B-From-the-MARCH-Study/default.aspx) 166. [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13518476/) 167. [WHO Global hepatitis report (2026)](https://iris.who.int/server/api/core/bitstreams/6f6caedc-37a0-49ee-a02a-df9c3b78ff42/content) 168. [WHO hepatitis B fact sheet (2026)](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b) 169. [WHO hepatitis B guidelines (2024)](https://iris.who.int/server/api/core/bitstreams/34470cc8-af90-4d7b-a949-ef27e5d0726f/content) 170. [Wong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8453838/) 171. [Wong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12823419/) 172. [Wong et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42411035/) 173. [Wong et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42803761/) 174. [Yang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10494462/) 175. [Yao et al. (2026)](https://doi.org/10.1186/s13561-026-00827-8) 176. [Ye et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34474097/) 177. [Yeo et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30342034/) 178. [Yilmaz et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42144799/) 179. [Younossi et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29505905/) 180. [Youssef et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11219612/) 181. [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/) 182. [Yuen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8516644/) 183. [Yuen et al. (2022)](https://www.nejm.org/doi/full/10.1056/NEJMoa2210027) 184. [Yuen et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36947478/) 185. [Yuen et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37442152/) 186. [Yuen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39389081/) 187. [Yuen et al. (2025)](https://www.arbutusbio.com/wp-content/uploads/2025/05/EASL-2025_THU-260-Yuen-MF-et-al.-IM-PROVE-I_FINAL.pdf) 188. [Yuen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42173110/) 189. [Zhou and Terrault (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8028744/) 190. [Zoulim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38971531/) ## Related pages - [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Terms and abbreviations](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations.md) - [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product information and disease description](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Clinical evidence](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Economic information and modeling report](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: new drug review](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses.md)